PDF
ePub
Citation
Print
Abstract
Background/Aims
Helicobacter pylori (H. pylori) is closely related with a wide range of gastrointestinal disease. One-week triple therapy is currently considered as the golden standard for the treatment of H. pylori infection. However, gastrointestinal abnormal responses are major pitfalls in such regimen. The aim of this study was to identify symptoms, frequency and severity of antibiotics-associated gastrointestinal abnormal responses during H. pylori eradication therapy.
Methods
Sixty-seven patients with H. pylori infection between September 2005 and March 2006 were included. After 1 week of H. pylori eradication triple therapy (rabeprazol 10 mg, clarithromycin 500 mg, amoxicillin 1 g bid), we evaluated gastrointestinal abnormal responses (diarrhea, bloating, constipation, abdominal pain, borborygmus, flatulence, stool frequency, belching, and nausea) and severities every week for 4 weeks.
Results
The incidence of diarrhea was the highest in week 1, which was 41.28% (n=28) and the lowest in week 4, which was 9.52% (n=6) and decreased from week 1 to week 4 with statistical significance (p＜0.0001). The most common gastrointestinal abnormal responses were associated with flatulence in week 1 (n=21, 31.34%), week 2 (n=21, 33.33%) and abdominal distention in week 3 (n=16, 25.40%), week 4 (n=15, 23.81%). Most of gastrointestinal abnormal responses were mild, and the most common symptom with higher than moderate grade was abdominal pain (n=4, 40.00%) in week 1. Alcohol consumption and coexisting medical illness were not associated with diarrhea (p=0.0852, 0.9009 respectively).
Conclusions
H. pylori eradication therapy is commonly associated with antibiotics-associated gastrointestinal abnormal responses, which may result in antibiotics intolerance and H. pylori eradication failure. Even though those symptoms are not so severe, we have to consider the gastrointestinal abnormal responses associated with H. pylori eradication, especially diarrhea.
REFERENCES
1. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut. 1997; 41:8–13.
2. Danese S, Armuzzi A, Romano A, et al. Efficacy and toler-ability of antibiotics in patients undergoing H. pylori eradication. Hepatogastroenterology. 2001; 48:465–467.
3. Cammarota G, Cannizzaro O, Ojetti V, et al. Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000; 14:73–77.
4. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multi-step strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000; 14:79–83.
5. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56:772–781.
6. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009; 54:269–278.
7. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol. 1995; 30:401–407.
8. Adamsson I, Nord CE, Lundquist P, Sjöstedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother. 1999; 44:629–640.
9. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis Suppl. 1986; 49:64–72.
10. de Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain C, Tytgat GN. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol. 1996; 8:641–643.
11. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127–1131.
12. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez- Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132–1136.
13. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175–1186.
14. Makola D, Peura DA, Crowe SE. Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol. 2007; 41:548–558.
15. Cremonini F, Gasbarrini A, Armuzzi A, Gasbarrini G. Helicobacter pylori-related diseases. Eur J Clin Invest. 2001; 31:431–437.
16. Armuzzi A, Gasbarrini A, Gabrielli M, Cremonini F, Anti M, Gasbarrini G. Helicobacter pylori and gastric carcinoma. Ann Ital Chir. 2001; 72:5–11.
17. Park HS, Han DS. Management of antibiotics-associated diarrhea. Korean J Gastroenterol. 2009; 54:5–12.
18. Arai T, Matsumoto J, Odajima H, Shimojo H, Kosugi H, Kondo T. A clinical study of antibiotic-associated acute hemorrhagic colitis, with special reference of Clostridium difficile. Nippon Shokakibyo Gakkai Zasshi. 1985; 82:78–85.
19. Peters DH, Clissold SP. Clarithromycin. A review of its anti-microbial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992; 44:117–164.
20. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25:155–168.
21. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002; 97:2744–2749.
22. Peura D. Helicobacter pylori: rational management options. Am J Med. 1998; 105:424–430.
23. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control. 2007; 35:131137.
24. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004; 38:475–483.
25. You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008; 148:632–633.
26. Lewis SJ, Freedman AR. Review article: the use of bio-therapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther. 1998; 12:807–822.
27. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003; 17:509–515.
28. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associa-ted gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001; 15:163–169.
29. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004; 20:1181–1188.
Table 1.
Baseline Characteristics of Study Group
Table 2.
Inciden nce of Loo ose Stool/Diar rrhea (%)
| Week 1 | Week 2 | Week 3 | Week 4 | |
|---|---|---|---|---|
| Incidence (%) |
41.28 (28/67) |
22.22 (14/63) |
11.11 (7/63) |
9.52 (6/63) |
Table 3.
Frequency of Loose Stool/Diarrhea (%)
| Week 1 | Week 2 | Week 3 | Week 4 | |
|---|---|---|---|---|
| Frequency (Mean± SD) | 2.46±1.82 | 2.93±2.37 | 2.14±1.77 | 1.67±1.21 |
Table 4.
Incidence of H. pylori Eradication Associated Gastrointestinal Side-Effects (%)
Table 5.
Symptom Grade of H. pylori Eradication Associated Gastrointestinal Side-Effects (Week 1)
XML Download